STEM CELL MEDICINE LTD has a total of 35 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2011. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and computer technology are GLIDDEN PAUL, HEMISPHERX BIOPHARMA and ALTIMMUNE INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 6 | |
#2 | United States | 6 | |
#3 | WIPO (World Intellectual Property Organization) | 5 | |
#4 | Australia | 4 | |
#5 | Canada | 4 | |
#6 | China | 4 | |
#7 | Brazil | 2 | |
#8 | Hong Kong | 2 | |
#9 | Japan | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Computer technology | |
#4 | IT methods for management | |
#5 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Marom Ehud | 21 |
#2 | Grynspan Frida | 13 |
#3 | Mor Felix | 10 |
#4 | Cohen Irun R | 8 |
#5 | Yudin Dima | 6 |
#6 | Bleich Kimelman Nadav | 4 |
#7 | Kimelman Nadav | 3 |
#8 | Irun R Cohen | 2 |
#9 | Felix Mor | 2 |
#10 | Cohen Irun R R | 2 |
Publication | Filing date | Title |
---|---|---|
EP3624816A1 | Treatment of multiple sclerosis with adipose-derived stem cells | |
WO2018002930A1 | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells | |
EP3624815A1 | Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells | |
US2014304012A1 | Insurance policies for stem cells depositors and methods for providing same | |
AU2012311051A1 | Beta-lactam compounds for enhancing T cell -mediated immune responses | |
CN104023721A | Beta-lactam compounds for treating diabetes | |
CA2798571A1 | Stem cell bank for personalized medicine |